Reaction
Endometrial Hyperplasia reporting signals
As of the last recalculation, Endometrial Hyperplasia appears in 803 FAERS reports alongside 9 co-occurring drug terms. The strongest observed disproportionality signal is RALOXIFENE HYDROCHLORIDE (PRR 36.4).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Raloxifene Hydrochloride | 20 | 36.4 | 36.4 |
| Progesterone | 30 | 35.3 | 35.3 |
| Anastrozole | 34 | 25.0 | 25.0 |
| Goserelin | 12 | 23.5 | 23.5 |
| Medroxyprogesterone Acetate | 32 | 17.3 | 17.3 |
| Conjugated Estrogens And Medroxyprogesterone Acetate | 11 | 12.2 | 12.2 |
| Etonogestrel And Ethinyl Estradiol | 10 | 11.8 | 11.8 |
| Levonorgestrel | 69 | 9.6 | 9.6 |
| Copper | 10 | 6.1 | 6.1 |